An Open-Label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02–Positive Adult Patients with Unresectable, Advanced, And/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined